Promoter methylation of Wnt/β-Catenin signal inhibitor is associated with unfavorable prognosis of non-small cell lung cancer.

: Recent research has indicated that altered promoter methylation of oncogenes and tumor suppressor genes is an important mechanism in lung cancer development and progression. In this study, we investigated the association between promoter methylation of , a possible inhibitor of the Wnt/β-Catenin signaling, and the survival of patients with non-small cell lung cancer (NSCLC). : Twelve pairs of tumor and adjacent non-tumor samples were used for microarray analyses of DNA methylation and gene expression. For validation, more than two hundred additional samples were analyzed for methylation using bisulfite pyrosequencing and for gene expression using qRT-PCR. Then the cell function were tested by wound healing, transwell, CCK8 and cell cycle assay. : Our analysis of patient specimens showed that methylation was higher in NSCLC tumors (82.2% ± 10.3, < 0.01) compared with the adjacent normal tissues (65.9% ± 7.2). The survival analysis revealed that patients with high methylation had a shorter overall survival (46 months) compared with patients with low methylation (>56 months;=0.021). In addition, we found that demethylation treatment could inhibit tumor cell proliferation, migration, and invasion, which was supportive of an association between methylation and survival. : Based on these consistent observations, we concluded that may play an important role in NSCLC progression and that promoter methylation of may serve as a biomarker for NSCLC prognosis and treatment.